Patents by Inventor Sankha Pattanayak

Sankha Pattanayak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10919857
    Abstract: An oligo-guanidine as cell penetrating agents/carriers includes a heterocyclic ring including 4-aminopiperidine, piperazine, morpholine having at least one N-terminal based heterocyclic ring or at least one O-heteroatom based heterocyclic ring tailored with hydrophobic and/or lipophilic group. The oligo-guanidine is adapted as an effective molecular transporter to transport and/or delivery therapeutics, therapeutic candidates, probes, or other molecules of interest across biological barriers including oligonucleotides. Advantageously, the oligo-guanidine is capable of being internalized into cells (in-vitro and in-vivo) with enhanced cellular uptake in nanomolar concentration.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 16, 2021
    Assignee: INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE
    Inventors: Surajit Sinha, Jhuma Bhadra, Sankha Pattanayak, Jayanta Kundu
  • Patent number: 10508116
    Abstract: Disclosed herein are Click Nucleic Acid Polymers (CNA-polymers) that comprise repeating dimer, trimer and tetramer units. The disclosed polymers can be used for antisense applications, for example, in treatment of “trinucleotide repeat disorders, i.e., Huntington's Disease and the like.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: December 17, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY
    Inventors: Christopher N. Bowman, Weixian Xi, Sankha Pattanayak
  • Publication number: 20190002408
    Abstract: An oligo-guanidine as cell penetrating agents/carriers includes a heterocyclic ring including 4-aminopiperidine, piperazine, morpholine having at least one N-terminal based heterocyclic ring or at least one O-heteroatom based heterocyclic ring tailored with hydrophobic and/or lipophilic group. The oligo-guanidine is adapted as an effective molecular transporter to transport and/or delivery therapeutics, therapeutic candidates, probes, or other molecules of interest across biological barriers including oligonucleotides. Advantageously, the oligo-guanidine is capable of being internalized into cells (in-vitro and in-vivo) with enhanced cellular uptake in nanomolar concentration.
    Type: Application
    Filed: June 10, 2016
    Publication date: January 3, 2019
    Inventors: Surajit SINHA, Jhuma BHADRA, Sankha PATTANAYAK, Jayanta KUNDU
  • Patent number: 10017510
    Abstract: Click thiol-X monomers and polymers containing such monomers are disclosed. The clickable sequence controllable monomers include an optionally protected thiol moiety; an optionally protected Michael acceptor moiety; a primary functional side chain and one ore more secondary functional side chains. A clickable sequence controllable monomer, can have the structure: wherein independently Y and Z are atoms having a valence electrons of 3 or more; n is a integer from 0-10; m is a integer from 0-10; x is a integer from 0-10; PFS is a functional group SFSi; SFS2; and SFS3 are independently a combination of hydrogen, hydroxyl, aromatic, amine, carboxyl, and carbonyls, optionally substituted to form hydrophilic, hydrophobic, amphiphilic, or charged (positive or negative or both) side chains; T is an optionally protected thiol; and TCA is an optionally protected thiol-click acceptor. Methods of using such polymers are also disclosed.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: July 10, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Christopher N. Bowman, Christopher J. Kloxin, Weixian Xi, Tao Gong, Sankha Pattanayak
  • Publication number: 20180100036
    Abstract: Disclosed herein are Click Nucleic Acid Polymers (CNA-polymers) that comprise repeating dimer, trimer and tetramer units. The disclosed polymers can be used for antisense applications, for example, in treatment of “trinucleotide repeat disorders, i.e., Huntington's Disease and the like.
    Type: Application
    Filed: October 6, 2017
    Publication date: April 12, 2018
    Inventors: Christopher N. Bowman, Weixian Xi, Sankha Pattanayak
  • Patent number: 9914745
    Abstract: Morpholino-based oligomers suitable as antisense agent comprising modifications of phosphorodiamidate backbone or modification with 5-substituted pyrimidines of morpholino compound that is soluble in culture medium and sufficient for cell penetration thereby eliminating the need for injecting into the cells. Monomers comprising the said oligomers and its method of manufacture, method of manufacture of the said oligomers and its dye, fluorophore, drug, biomolecule conjugate wherein the said oligomers find different end use but not limited to regulation of gene expression, tissue culture with improved transfection efficiency and related studies on cellular transfection.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: March 13, 2018
    Assignee: INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE
    Inventors: Surajit Sinha, Sankha Pattanayak, Sibasish Paul, Bappaditya Nandi
  • Publication number: 20170015667
    Abstract: Click thiol-X monomers and polymers containing such monomers are disclosed. The clickable sequence controllable monomers include an optionally protected thiol moiety; an optionally protected Michael acceptor moiety; a primary functional side chain and one ore more secondary functional side chains. A clickable sequence controllable monomer, can have the structure: wherein independently Y and Z are atoms having a valence electrons of 3 or more; n is a integer from 0-10; m is a integer from 0-10; x is a integer from 0-10; PFS is a functional group SFSi; SFS2; and SFS3 are independently a combination of hydrogen, hydroxyl, aromatic, amine, carboxyl, and carbonyls, optionally substituted to form hydrophilic, hydrophobic, amphiphilic, or charged (positive or negative or both) side chains; T is an optionally protected thiol; and TCA is an optionally protected thiol-click acceptor. Methods of using such polymers are also disclosed.
    Type: Application
    Filed: February 6, 2015
    Publication date: January 19, 2017
    Inventors: Christopher N. BOWMAN, Christopher J. KLOXIN, Weixian XI, Tao GONG, Sankha PATTANAYAK
  • Publication number: 20120296087
    Abstract: Morpholino-based oligomers suitable as antisense agent comprising modifications of phosphorodiamidate backbone or modification with 5-substituted pyrimidines of morpholino compound that is soluble in culture medium and sufficient for cell penetration thereby eliminating the need for injecting into the cells. Monomers comprising the said oligomers and its method of manufacture, method of manufacture of the said oligomers and its dye, flurophore, drug, biomolecule conjugate wherein the said oligomers find different end use but not limited to regulation of gene expression, tissue culture with improved transfection efficiency and related studies on cellular transfection.
    Type: Application
    Filed: August 10, 2010
    Publication date: November 22, 2012
    Applicant: INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE
    Inventors: Surajit Sinha, Sankha Pattanayak, Sibasish Paul, Bappaditya Nandi